Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther 2018; 9(7): 63-68 [PMID: 30595950 DOI: 10.4292/wjgpt.v9.i7.63]
Corresponding Author of This Article
Prashanth Rawla, MD, Doctor, Department of Internal Medicine/Hospitalist, SOVAH Health, 320 Hospital Dr, Martinsville, VA 24112, United States. rawlap@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. Dec 13, 2018; 9(7): 63-68 Published online Dec 13, 2018. doi: 10.4292/wjgpt.v9.i7.63
Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
Prashanth Rawla, Tagore Sunkara, Andrew Ofosu, Vinaya Gaduputi
Prashanth Rawla, Department of Internal Medicine, SOVAH Health, Martinsville, VA 24112, United States
Tagore Sunkara, Andrew Ofosu, Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY 11201, United States
Vinaya Gaduputi, Division of Gastroenterology, SBH Health System, Bronx, NY 10457, United States
Author contributions: Rawla P, Sunkara T and Ofosu A participated in the conception and design of this study; Rawla P, Sunkara T, Ofosu A and Gaduputi V participated equally in the analysis, interpretation, drafting, critical revisions and final approval of the article.
Conflict-of-interest statement: All authors have no conflicts of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Prashanth Rawla, MD, Doctor, Department of Internal Medicine/Hospitalist, SOVAH Health, 320 Hospital Dr, Martinsville, VA 24112, United States. rawlap@gmail.com
Telephone: +1-276-6667200 Fax: +1-276-6667394
Received: August 27, 2018 Peer-review started: August 27, 2018 First decision: October 8, 2018 Revised: October 24, 2018 Accepted: November 26, 2018 Article in press: November 26, 2018 Published online: December 13, 2018 Processing time: 108 Days and 6.7 Hours
Abstract
The modern lifestyle caters to an increase in the incidence of peptic ulcer disease, gastroesophageal reflux disease and several other acid-related conditions of the gut. The drugs to prevent these conditions work either through H2 receptor blockade or inhibition of the H+, K+ ATPase enzyme. Although proton pump inhibitors have been proven to be efficacious, they have a slow onset of action with limited resolution of symptoms in most patients. Potassium-competitive acid blockers (P-CABs) are novel drugs that bind reversibly to K+ ions and block the H+, K+ ATPase enzyme, thus preventing acid production. P-CABs have a fast onset of action and have dose-dependent effects on acid production. Animal studies exist that differentiate the better results of P-CABs from proton pump inhibitors; further human trials will give a comprehensive picture of the results and will help to elucidate the therapeutic benefits of this new group of drugs.
Core tip: There have been tremendous changes in the treatment of acid-related diseases. In this rapidly evolving field, novel drugs such as potassium-competitive acid blockers (P-CABs) show promising potential. This review aims to provide a perspective on this new class of drugs by summarizing the mechanism of action, therapeutic benefits, adverse effects and approval status of various P-CABs in the market.
